Frank Wagner

SCH 503034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon α-2b for Genotype 1 Nonresponders

Christoph Sarrazin, Frank Wagner, Nicole Forestier et al. · Gastroenterology · 2007 · 311 citations

Hepatology, Viral Hepatitis, Immunology +10

Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study

Alain C. Tissot, Patrik Maurer, Juerg Nussberger et al. · The Lancet · 2008 · 284 citations

Hypertension, Angiotensin Ii, Cardiovascular Disease +8

Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

James G. Krueger, Laura K. Ferris, Alan Menter et al. · Journal of Allergy and Clinical Immunology · 2015 · 246 citations

Immunology, Clinical Trials, Biomarker Results +8

A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity

Patrice M. Ambühl, Alain C. Tissot, Alma Fulurija et al. · Journal of Hypertension · 2006 · 218 citations

Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity

Thomas Dörner, Maximilian Posch, Yue Li et al. · Annals of the Rheumatic Diseases · 2019 · 189 citations